<DOC>
	<DOCNO>NCT02688998</DOCNO>
	<brief_summary>In REaCT-Vascular Access Her2 negative study , investigator use novel method allow comparison establish standard care vascular access strategy use `` integrated consent model '' part pragmatic clinical trial . Determining optimal vascular access strategy remain important medical issue patient , nurse , physician society . A novel method allow comparison establish standard care need part increase internationally mandate incentive perform pragmatic clinic trial .</brief_summary>
	<brief_title>REaCT-vascular Access Her2 Negative Vascular Access Strategies ( Neo ) Adjuvant Breast Cancer Treatment Without Trastuzumab</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Histologically confirm primary breast cancer Planned start either FECD , ACD , dosedense ACT , TAC , TC chemotherapy , adjuvant neoadjuvant setting . ≥19 year age Able provide verbal consent • Contraindication central line placement .</criteria>
	<gender>Female</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>HER2 negative</keyword>
</DOC>